Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progression in chronic kidney disease.

Allison A Eddy1

  • 1Division of Nephrology, University of Washington and Children's Hospital and Regional Medical Center, Seattle, WA 98105, USA. allison.eddy@seattlechildrens.org

Advances in Chronic Kidney Disease
|October 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient and caregiver perspectives on mental health in children and adolescents with chronic kidney disease.

Clinical kidney journal·2025
Same author

Patient, Parental, and Health Professional Perspectives on Growth in Children With CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2024
Same author

Child and caregiver perspectives on access to psychosocial and educational support in pediatric chronic kidney disease: a focus group study.

Pediatric nephrology (Berlin, Germany)·2022
Same author

Perspectives of Clinicians on Shared Decision Making in Pediatric CKD: A Qualitative Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2022
Same author

Patient and caregiver perspectives on blood pressure in children with chronic kidney disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2021
Same author

Impact of training nephrologists from developing nations and strategies for sustaining a training program in its fourth decade.

Kidney international·2021

Chronic kidney disease (CKD) involves kidney fibrosis, capillary loss, and nephron destruction. Targeting multiple fibrotic pathways, including transforming growth factor beta (TGF-beta), is key for new CKD therapies.

Area of Science:

  • Nephrology
  • Pathology
  • Molecular Biology

Background:

  • Chronic kidney disease (CKD) pathogenesis involves interstitial fibrosis, capillary loss, hypoxia, and tubular atrophy.
  • Early stages of kidney fibrosis feature inflammatory leukocyte and myofibroblast recruitment.
  • Macrophages play complex roles, secreting fibrosis-promoting molecules but also potentially aiding in clearance.

Purpose of the Study:

  • To elucidate the common pathogenic mechanisms leading to progressive kidney fibrosis in CKD.
  • To identify key cellular players and molecular pathways driving interstitial fibrosis and nephron destruction.
  • To explore potential therapeutic targets within the fibrogenic cascade.

Main Methods:

  • Review and synthesis of existing literature on CKD pathogenesis.

Related Experiment Videos

  • Analysis of cellular recruitment and differentiation processes in kidney fibrosis.
  • Examination of molecular signaling pathways, including growth factors and matrix-degrading enzymes.

    • Main Results:

    • CKD progression converges on interstitial fibrosis, capillary loss, and nephron destruction.
    • Myofibroblasts, originating from diverse cell types, are central to extracellular matrix accumulation.
    • Transforming growth factor beta (TGF-beta) is a critical mediator, alongside other fibrogenic molecules like connective tissue growth factor and plasminogen activator inhibitor-1.
    • Reduced levels of antifibrotic factors (e.g., hepatocyte growth factor, bone morphogenic protein-7) exacerbate fibrosis.

    Conclusions:

    • CKD progression is driven by a complex interplay of cellular recruitment and molecular signaling.
    • Targeting multiple components of the fibrogenic cascade, including TGF-beta, is essential for effective CKD therapy.
    • Further research into antifibrotic factors and matrix-degrading proteases may reveal new therapeutic strategies.